Inclusion Criteria:  Pathologically proven diagnosis of prostate adenocarcinoma within 12 months of enrollment Unfavorable intermediate risk prostate cancer by NCCN 2021 risk stratification guidelines, including any of the following clinicopathologic features: Gleason Score 4+3 >50% biopsy cores positive  Two or more of the following risk factors:  Grade Group 2 or 3 cT2b-T2c PSA 10 - 20 ng/mL Able to undergo MRI for initial staging and MR based radiation planning Sufficient biopsy tissue available for Decipher genomic testing Prostate volume < 90cc IPSS ≤ 20 Age ≥ 18 KPS ≥ or ECOG 0-2 Estimated life expectancy >5 years Willing and able to provide written informed consent and Authorization for Use and Release of Health and Research Study Information (HIPAA authorization)  Exclusion Criteria:  Radiographic T3-T4 detected on staging mpMRI  °Must be "consistent with" (>90% probability) or suspicious for/probable/probably (75%-90% probability) ofT3-T4 disease determined by the reading radiologist.  Evidence of distant metastases as determined by MRI, PET, or CT imaging Evidence of pelvic lymph node involvement as determined by MRI, PET, or CT imaging Prior treatment for prostate cancer including chemotherapy, surgery, or hormonal therapy Prior pelvic radiation Active second malignancy or past history of malignancies diagnosed within the last 2 years that requires active therapy and/or in remission, with the exception of resected non-melanoma skin cancers, non-muscle invasive bladder cancer, stage I head and neck cancer, or stage I colorectal cancer TURP or greenlight PVP within 6 months of enrollment History of Crohn's Disease or Ulcerative Colitis